

Scott T. McFarland is a Policy Advisor in the Office of In Vitro Diagnostics and Radiological Health (OIR), CDRH, FDA. His responsibilities include leading the de novo and 513(g) programs for OIR, developing guidance and regulations for OIR, and co-leading the CDRH third party premarket review program. He has served at FDA in varying roles since 2005. Mr. McFarland received his JD from the College of William and Mary and his BS in Biology from Virginia Polytechnic Institute and State University.